去年国产疫苗在海外卖了3亿多美元，连续两年在增长

Group 1 - In 2025, China's vaccine exports reached $324 million, a year-on-year increase of 52.63% after recovering to positive growth in 2024 [1] - The export amount in 2024 was $212 million, marking a 4.92% increase, which was the first positive growth since 2022 [1] - China exported vaccines to 85 global markets in 2025, with the top ten markets accounting for 70.04% of the total exports [1] Group 2 - Chinese vaccine companies are increasingly expanding overseas, leveraging opportunities in developing countries along the "Belt and Road" initiative [2] - Kangtai Biological announced a revenue increase in 2025, with overseas business revenue reaching approximately 98.84 million yuan, a year-on-year increase of 859.40% [2] - Wantai Biological reported significant growth in international markets for its bivalent HPV vaccine, indicating successful international market expansion [2] Group 3 - The growth in vaccine exports in 2025 is primarily driven by volume rather than price, with a volume increase of 130.54% indicating a "volume up, price down" trend [3] - Vaccine imports in China have been on the rise since 2014, but began to decline in 2024, with a significant drop in batch issuance for multiple products [3] - The decline in imported vaccines is attributed to advancements in domestic vaccine production capabilities, with several major products like the nine-valent HPV vaccine and shingles vaccine being launched and gaining market share [3]